GeneCentric Therapeutics Presents First Data on Novel Response Signatures to Treatment in Muscle Invasive Bladder Cancer (MIBC) Patients
Data presented at 2019 ASCO Annual Meeting DURHAM, N.C.–(BUSINESS WIRE)–GeneCentric Therapeutics will present the first data on novel response signatures…